Fact CheckerSign in

NCT06419946RecruitingPhase 3

Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma

Phase III Trial of Temozolomide/Lomustine (TMZ/LOM) Combination Therapy vs. Standard TMZ Therapy for Newly Diagnosed MGMT Promoter Methylated Glioblastoma (IDHwt) Patients +/- Tumor Treating Fields (Optune)

Source: ClinicalTrials.gov · Last updated 13 Apr 2026

Brief summary (registry, in English)

Background: Glioblastoma (GBM) is notoriously difficult to treat, with current therapies often extending life by only a few months. The standard treatment involves surgery followed by radiation and chemotherapy with Temozolomide (TMZ). The efficacy of TMZ, however, is significantly enhanced when the tumor's o6-methylguanine-DNA-methyltransferase (MGMT) gene is methylated. Recent studies, such as the NOA-09 trial, have suggested that adding Lomustine (LOM) to TMZ could improve outcomes for patients with this specific tumor profile. Hypothesis: The investigators hypothesize that the addition of LOM to the TMZ regimen will lead to significantly improved survival rates among patients with newly diagnosed glioblastoma who have a methylated MGMT promoter compared to those receiving only TMZ. Treatment Plans: The study will randomly assign participants to two groups: * Control Group: Standard treatment with TMZ during and after radiation therapy. * Experimental Group: TMZ combined with LOM, starting on the first day of radiation therapy. Outcome Measures: The primary outcome measure will be survival. Other outcomes will include progression-free survival (time from randomization until tumor progression or death), safety profiles (adverse effects of the treatments), and quality of life measures as well as neurocognitive outcomes.

Status (registry)
Recruiting
Phase (registry)
Phase 3
Study type
Interventional
Enrollment
200 (estimated)
First submitted
29 Apr 2024
Start date
1 Feb 2025
Primary completion date
15 Dec 2031
Lead sponsor
Vastra Gotaland Region
Diseases
Glioblastoma
NCT number
NCT06419946

What you commit to

  • Study type: Interventional · Phase 3
  • Planned participants: 200
  • From 1 Feb 2025 to the primary completion date, 15 Dec 2031
  • 20 sites in 4 countries
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Previous chemotherapy or radiotherapy involving the head

Other illness

  • Previous malignancy within 3 y or malignancy treated non-curatively

Other

  • Off-protocol tumor-specific treatment
  • Serious comorbidity

Who the study is looking for

  • Newly diagnosed glioblastoma/gliosarcoma, IDH wild type
  • Methylated MGMT promoter
  • World Health Organization performance status 0-2
  • Age 18-70

Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (20)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
University Hospital Graz
Coordinator of this site? Confirm its status
GrazAustriaNot yet recruiting
Medizinische Universität Innsbruck
Coordinator of this site? Confirm its status
InnsbruckAustriaNot yet recruiting
Kepler University Hospital
Coordinator of this site? Confirm its status
LinzAustriaRecruiting
University Hospital St. Pölten
Coordinator of this site? Confirm its status
Sankt PöltenAustriaEnrolling by invitation
Aarhus University Hospital
Coordinator of this site? Confirm its status
AarhusDenmarkRecruiting
Haukeland University Hospital
Coordinator of this site? Confirm its status
BergenNorwayRecruiting
Sorlandet Sykehus
Coordinator of this site? Confirm its status
KristiansandNorwayRecruiting
Oslo University Hospital
Coordinator of this site? Confirm its status
OsloNorwayRecruiting
Stavanger University Hospital
Coordinator of this site? Confirm its status
StavangerNorwayNot yet recruiting
St Olavs Hospital
Coordinator of this site? Confirm its status
TrondheimNorwayNot yet recruiting
Gävle Hospital
Coordinator of this site? Confirm its status
GävleSwedenRecruiting
Sahlgrenska University Hospital
Coordinator of this site? Confirm its status
GothenburgSwedenRecruiting
Ryhov County Hospital
Coordinator of this site? Confirm its status
JönköpingSwedenRecruiting
Kalmar Country Hospital
Coordinator of this site? Confirm its status
KalmarSwedenRecruiting
Skåne University Hospital
Coordinator of this site? Confirm its status
LundSwedenNot yet recruiting
Örebro University Hospital
Coordinator of this site? Confirm its status
ÖrebroSwedenRecruiting
Karolinska Institutet
Coordinator of this site? Confirm its status
StockholmSwedenEnrolling by invitation
Sundsvall Hospital
Coordinator of this site? Confirm its status
SundsvallSwedenEnrolling by invitation
Norrlands Universitetssjukhus, Umea, Sweden
Coordinator of this site? Confirm its status
UmeåSwedenRecruiting
Uppsala University Hospital
Coordinator of this site? Confirm its status
UppsalaSwedenRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.